2 Biotech Stocks to Buy in May
The stock market has performed relatively well since the beginning of the year although, of course, there is no guarantee that it will maintain that momentum. Who knows what curve ball the future has in store for us? Regardless of what happens, investing in market leaders with robust underlying businesses and excellent prospects is still usually a good idea.
Let's consider two such stocks in the biotech industry: Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron Pharmaceuticals (NASDAQ: REGN). Find out why these drugmakers are worth investing in today.
Cystic fibrosis (CF) is a rare genetic disease that causes thick mucus that hinders the normal functioning of the lungs, pancreas, and other internal organs. Vertex Pharmaceuticals has developed several medicines that address the underlying causes of CF, the only ones in the world. The biotech's monopoly in this area has famously allowed it to generate growing revenue and profits.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Die Community bevorzugt Vertex Pharmaceuticals Inc., mit deutlich mehr Buy- (42) als Sell-Einschätzungen (1).
Ein Kursziel von 474 € für Vertex Pharmaceuticals Inc. impliziert ein leicht positives Wachstum gegenüber dem aktuellen Kurs von 436.9 €.
